Vanguard Capital Management Reports New 5.23% Stake in Neurocrine Biosciences Inc (NBIX)

Vanguard Capital Management LLC filed a Schedule 13G on April 30, 2026, disclosing a new 5.23% ownership stake in Neurocrine Biosciences Inc (NBIX). As of the event date of March 31, 2026, the firm beneficially owns 5,257,941 shares of common stock. The filing indicates that Vanguard holds sole dispositive power over all 5,257,941 shares, while possessing sole voting power over 746,037 shares. This position was acquired in the ordinary course of business and is not intended to influence or change the control of the issuer. The reported holdings include securities managed by various Vanguard affiliates, such as Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. Previously, the filer reported 0.0% ownership, marking this as a significant new institutional position in the biopharmaceutical company. The total value of the holdings is estimated at approximately $692.89 million based on the reported share count.